Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Review Article Volume 5 Issue 10

Bisphosphonate Use in Childhood

Jomaa Olfa1*, Jguirim Mahbouba1, Rim Klii2, Ardhaoui Mahbouba1, Bejia Ismail1, Touzi Monji1, Bergaoui Naceur1

1Department of Rheumatology, University of Monastir, Fattouma Bourguiba Hospital, Tunisia
2Department of Internal Medicine, University of Monastir, Fattouma Bourguiba Hospital, Tunisia

*Corresponding Author: Jomaa Olfa, Department of Rheumatology, University of Monastir, Fattouma Bourguiba Hospital, Tunisia.

Received: August 30, 2021; Published: September 18, 2021

Abstract

  Bisphosphonates are structural analogues of inorganic pyrophosphate that are potent inhibitors of bone resorption. In pediatric rheumatology, the main indications of bisphosphonates are primary osteoporosis as idiopathic juvenile osteoporosis, osteogenesisimperfecta, osteoporosis secondary to chronic rheumatological, endocrine, immobilization, or gastrointestinal disorders, tissucalcinosis and dermatomyosistis.

  Several pediatric studies have been conducted, mainly in osteogenesis imperfecta and chronic rheumatic diseases. The results obtained with bisphosphonates, especially with pamidronate and alendronate were promising. The use of bisphosphonates should be reserved for children severely affected by a symptomatic osteoporosis. These children should be included in clinical studies with long term monitoring. The regimens reported were cyclic infusion of pamidronate at 0,5 to 1 mg/kg/dose with a cumulative dose not exceeding 9 mg/kg/year. The dose suggested for alendronate were 5 mg once daily or 35 mg once a week for children less than 30 kg and 10 mg once daily or 70 mg once weekly for more than 30 kg. Treatment protocols must be defined especially with recent bisphosphonates, particularly effectives.

  Suppose efficacy and tolerability of bisphosphonates in short terms are encouraging. In that case, the duration of treatment and the long-term toxicity, especially in subsequent pregnancies, require further studies.

Keywords: Osteoporosis; Osteogenesisimperfecta; Children; Bisphosphonates; Pediatric DXA; Pamidronate

References

  1. Delalande D., et al. “Les ostéoporoses juvéniles Juvenile osteoporosis”. Archives of Pediatrics4 (2008): 420-30.
  2. Russell RG. “Bisphosphonates: mode of action and pharmacology”. Pediatrics2 (2007): 150-162.
  3. Batch JA., et al. “. Use of bisphosphonatetherapy for osteoporosis in childhood and adolescence”. Journal of Paediatrics and Child Health 2 (2003): 88‐92.
  4. Kone Paut I., et al. “Les biphosphonates chez l'enfant: présent et avenir Biphosphonates in children: present and future”. Archives of Pediatrics8 (2002): 836-842.
  5. Abi Najm S., et al. “Bisphosphonates-related jaw osteonecrosis: mise au point”. Medecine Buccale Chirurgie Buccale 14 (2008): 5-18.
  6. Papapoulos SE and Cremers SC. “Prolonged bisphosphonate release after treatment in children”. The New England Journal of Medicine10 (2007): 1075-1076.
  7. Sebestyen JF., et al. “Bisphosphonates use in children”. Clinical Pediatrics (Phila)11 (2012): 1011-1024.
  8. Ezra A and Golomb G. “Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption”. Advanced Drug Delivery Reviews3 (2000): 175‐195.
  9. Russell RG., et al. “Bisphosphonates: pharmacology, mechanisms of action and clinical uses”. Osteoporosis International2 (1999): 66-80.
  10. Dorgeret S., et al. “L'ostéodensitométrie en pratique pédiatrique Bone densitometry in pediatric practice”. JBR-BTR5 (2004): 263-4.
  11. Gafni RI and Baron J. “Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy x-ray absorptiometry (DEXA)”. Journal of Pediatrics2 (2008): 253-257.
  12. Hogler W., et al. “Importance of lean mass in the interpretation of total body densitometry in children and adolescents”. Journal of Pediatrics1 (2003): 81-88.
  13. Bachrach LK and Ward LM. “Clinical review 1: Bisphosphonate use in childhood osteoporosis”. The Journal of Clinical Endocrinology and Metabolism2 (2009): 400-409.
  14. Wood CL and Ahmed SF. “Bone protective agents in children”. Archives of Disease in Childhood 5 (2018): 503-508.
  15. Rauch F and Glorieux FH. “Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?” Annals of Medicine4 (2005): 295-302.
  16. Forin V., et al. “Benefits of pamidronate inchildren with osteogenesis imperfecta : an open prospective study”. Joint Bone Spine4 (2005): 313-318.
  17. Ward LM., et al. “A randomized placebo controlled trial of oral alendronate children and adolescents with osteogenesis imperfecta”. Journal of Bone and Mineral Research 20 (2005): S1-S102.
  18. Zeitlin L., et al. “Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV”. Pediatrics 5 (2003): 1030-1036.
  19. Ward LM., et al. “Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study”. The Journal of Clinical Endocrinology and Metabolism2 (2011): 355-364.
  20. Vuorimies I., et al. “Zoledronic acid treatment in children with osteogenesis imperfecta”. Hormone Research in Paediatrics5 (2011): 346-353.
  21. Saraff V and Högler W. “ENDOCRINOLOGY AND ADOLESCENCE: Osteoporosis in children: diagnosis and management”. European Journal of Endocrinology6 (2015): R185-197.
  22. Kolyva S., et al. “Hypercalcemia and osteolytic lesions as presenting symptoms of acute lymphoblastic leukemia in childhood. The use of zoledronic acid and review of the literature”. Journal of Pediatric Endocrinology and Metabolism3-4 (2011): 349-354.
  23. Saraff V., et al. “Efficacy and treatment costs of zoledronate versus pamidronate in paediatric osteoporosis”. Archives of Disease in Childhood1 (2018): 92-94.
  24. Semler O., et al. “Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta”. Hormone Research in Paediatrics5 (2011): 321‐327.
  25. Gatti D., et al. “Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study”. Journal of Bone and Mineral Research5 (2005): 758‐763.
  26. Hoyer-Kuhn H., et al. “Osteogenesis imperfecta: pathophysiology and treatment”. Wien Med Wochenschr13-14 (2015): 278‐284.
  27. Semler O., et al. “Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesisimperfecta”. Hormone Research in Paediatrics5 (2011): 321-327.
  28. Bianchi Ml., et al. “Efficacity and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children : a prospective multicenter study”. Arthritis Rheum 43 (2000): 1960-1966.
  29. Rudge S., et al. “Effects of once-weekly oral alendronate on bone in children on glucocorticoidv treatment”. Rheumatology6 (2005): 813‐818.
  30. Bianchi ML., et al. “Treatment of low bone density in young people with cysticfibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate”. Lancet Respiratory Medicine 5 (2013): 377-385.
  31. Ward LM., et al. “The management of osteoporosis in children”. Osteoporosis International7 (2016): 2147-2179.
  32. Steelman J and Zeitler P. “Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions”. Journal of Pediatrics4 (2003): 417-423.
  33. Simm PJ., et al. “Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis”. Bone 5 (2011): 939-943.
  34. Lteif AN and Zimmerman D. “Bisphosphonates for treatment of childhood hypercalcemia”. Pediatrics 102 (1998): 990-993.
  35. Kerdudo C., et al. “Hypercalcémie chez l'enfant cancéreux”. Archives de pédiatrie6 (2005): 691-693.
  36. Poirée M., et al. “Hypercalcémie menaçante révélatrice d’une leucémie aiguë lymphoblastique de l’enfant”. Archives de pédiatrie6 (2015): 608-612.
  37. Guarino S., et al. “An infant with hypercalcemia: answers”. Pediatric Nephrology11 (2014): 2123-2125.
  38. Saggese G., et al. “Osteoporosis in children and adolescents: diagnosis, risk factors, and prevention”. Journal of Pediatric Endocrinology and Metabolism7 (2001): 833-859.
  39. Gandrud LM., et al. “Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis”. Journal of Pediatric Endocrinology and Metabolism6 (2003): 887-892.
  40. Dhivyasree S., et al. “A rare and unusual presentation of acute lymphoblastic leukemia”. Journal of Cancer Research and Therapeutics 12 (2018): 1244‐1246.
  41. Aragão AL., et al. “Oral Alendronate Treatment for Severe Polyostotic Fibrous Dysplasia due to McCune-Albright Syndrome in a Child: A Case Report”. International Journal of Pediatric Endocrinology 2010 (2010): 432060.
  42. Slimani S., et al. “Résolution complète d’une calcinose universelle compliquant une dermatomyosite juvénile traitée par pamidronate”. Revue du rhumatisme1 (2010): 91-93.
  43. Mukamel M., et al. “New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment”. Journal of Pediatrics5 (2001): 763-766.
  44. Ambler GR., et al. “Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy”. Journal of Rheumatology9 (2005): 1837-1839.
  45. Rothenbuhler A., et al. “Risk of corrected QT interval prolongation after pamidronate infusion in children”. The Journal of Clinical Endocrinology and Metabolism8 (2010): 3768-3770.
  46. Glorieux FH., et al. “Cyclic administration of pamidronate in children with severe osteogenesis imperfecta”. The New England Journal of Medicine14 (1998): 947-952.
  47. Plotkin H., et al. “Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age”. The Journal of Clinical Endocrinology and Metabolism5 (2000): 1846-1850.
  48. Martinez-Soto T., et al. “Treatment of symptomatic osteoporosis in children: a comparison of two pamidronate dosage regimens”. The Journal of Clinical Endocrinology and Metabolism5-6 (2011): 271-274.
  49. Siden H. “The boy who refused an IV: a case report of subcutaneous clodronate for bone pain in a child with Ewing Sarcoma”. Journal of Medical Case Reports 1 (2007): 7.
  50. Bishop N., et al. “Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions”. Journal of Clinical Densitometry2 (2014): 275-280.
  51. Plotkin H., et al. “Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age”. The Journal of Clinical Endocrinology and Metabolism 5 (2000): 1846-1850.
  52. Sarraf KM. “Images in clinical medicine. Radiographic zebra lines from cyclical pamidronate therapy”. The New England Journal of Medicine3 (2011): e5.
  53. Szadek LL and Scharer K. “Identification, prevention, and treatment of children with decreased bone mineral density”. Journal of Pediatric Nursing5 (2014): e3-14.
  54. Soybilgic A., et al. “A survey of steroid-related osteoporosis diagnosis, prevention and treatment practices of pediatric rheumatologists in North America”. Pediatric Rheumatology 12 (2014): 24.
  55. Ward LM., et al. “Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I”. The Journal of Clinical Endocrinology and Metabolism7 (2005): 4051-4056.
  56. Whyte MP., et al. “Bisphosphonate-induced osteopetrosis”. The New England Journal of Medicine 5 (2003): 457-463.
  57. Hegazy A., et al. “Unusual Femur Stress Fractures in Children With Osteogenesis Imperfecta and Intramedullary Rods on Long-term Intravenous Pamidronate Therapy”. Journal of Pediatric Orthopaedics 7 (2016): 757-761.
  58. Inoue Y., et al. “Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases”. Clinical Rheumatology7 (2008): 909-912.
  59. Kan SL., et al. “Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases: A meta-analysis”. Medicine (Baltimore)25 (2016): e3990.
  60. Hennedige AA., et al. “Systematic Review on the Incidence of Bisphosphonate Related Osteonecrosis of the Jaw in Children Diagnosed with Osteogenesis Imperfecta”. Journal of Oral and Maxillofacial Research: JOMR 4 (2014): e1.
  61. Malmgren B., et al. “No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates”. Journal of Oral Pathology and Medicine 4 (2008): 196-200.
  62. Brown JJ., et al. “Bisphosphonate-associatedosteonecrosis of the jaw: doesitoccur in children?”. Clinical Endocrinology (Oxf)6 (2008): 863‐867.
  63. Lietman SA., et al. “Hypercalcemia in children and adolescents”. Current Opinion in Pediatrics4 (2010): 508-515.

Citation

Citation: Jomaa Olfa., et al. “Bisphosphonate Use in Childhood”.Acta Scientific Medical Sciences 5.10 (2021): 82-91.

Copyright

Copyright: © 2021 Jomaa Olfa., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.111

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is October 20, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US